• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管壁中一种可能的新型血管紧张素II生成酶的证据。

Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall.

作者信息

Okunishi H, Miyazaki M, Toda N

出版信息

J Hypertens. 1984 Jun;2(3):277-84.

PMID:6099388
Abstract

An inhibitor of angiotensin I (ANG I) converting enzyme, SA446, reduced the response to ANG I of blood vessels isolated from dogs and monkeys, but did not abolish the response even at high concentrations. The residual action of ANG I in the presence of high concentrations of SA446 could be abolished by (Sar1, Ala8)-ANG II. Vascular strips and crude extracts of vessels and lungs possessed the enzymic activity generating ANG II from ANG I, or hippuric acid from hippuryl-histidyl-leucine (HHL). The HHL-hydrolysing activity of the crude extracts was completely inhibited by SA446 (10(-7) mol/l) and/or Na2-EDTA (10(-3) mol/l). However, the octapeptide generation was not abolished despite the combined treatment with SA446 (5 X 10(-4) mol/l) and Na2-EDTA (5 x 10(-3) mol/l). The residual activity forming ANG II was inhibited by chymostatin and soybean trypsin inhibitor, which however did not affect the HHL-hydrolysis. Combined treatment with SA446 (10(-5) mol/l) and chymostatin (2.5 X 10(-5) mol/l) abolished the vascular action of ANG I but did not alter the action of ANG II. These results strongly suggest that besides the ANG I converting enzyme, another enzyme which generates ANG II is present in vascular tissues and lungs, and may play an important role in the local generation of ANG II, which possibly regulates the regional vascular tone.

摘要

血管紧张素I(ANG I)转化酶抑制剂SA446可降低从犬和猴分离出的血管对ANG I的反应,但即使在高浓度下也不能完全消除该反应。在高浓度SA446存在时ANG I的残余作用可被(Sar1,Ala8)-ANG II消除。血管条以及血管和肺的粗提物具有将ANG I转化为ANG II或从马尿酰-组氨酰-亮氨酸(HHL)生成马尿酸的酶活性。粗提物的HHL水解活性被SA446(10^(-7)mol/L)和/或Na2-EDTA(10^(-3)mol/L)完全抑制。然而,尽管联合使用SA446(5×10^(-4)mol/L)和Na2-EDTA(5×10^(-3)mol/L),八肽生成并未被消除。形成ANG II的残余活性被抑肽酶和大豆胰蛋白酶抑制剂抑制,然而这两种抑制剂并不影响HHL水解。SA446(10^(-5)mol/L)和抑肽酶(2.5×10^(-5)mol/L)联合处理可消除ANG I的血管作用,但不改变ANG II的作用。这些结果强烈表明,除了ANG I转化酶外,血管组织和肺中还存在另一种生成ANG II的酶,它可能在ANG II的局部生成中起重要作用,而ANG II可能调节局部血管张力。

相似文献

1
Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall.血管壁中一种可能的新型血管紧张素II生成酶的证据。
J Hypertens. 1984 Jun;2(3):277-84.
2
Conversion of angiotensin I to angiotensin II in dog isolated renal artery: role of two different angiotensin II-generating enzymes.犬离体肾动脉中血管紧张素I向血管紧张素II的转化:两种不同血管紧张素II生成酶的作用。
J Cardiovasc Pharmacol. 1990 Mar;15(3):353-9. doi: 10.1097/00005344-199003000-00002.
3
Antihypertensive mechanism of an angiotensin converting enzyme inhibitor, SA446, in dogs.
Bull Osaka Med Coll. 1989 Nov;35(1-2):29-37.
4
Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells.高糖诱导大鼠血管平滑肌细胞产生血管紧张素II的机制
Circ Res. 2007 Aug 31;101(5):455-64. doi: 10.1161/CIRCRESAHA.107.151852. Epub 2007 Jul 12.
5
Human-derived vascular smooth muscle cells produce angiotensin II by changing to the synthetic phenotype.人源血管平滑肌细胞通过转变为合成表型来产生血管紧张素II。
J Cell Physiol. 2003 Aug;196(2):284-92. doi: 10.1002/jcp.10299.
6
A new potent inhibitor of converting enzyme: (2R,4R)-2-(2-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarboxylic acid(SA446).
Jpn J Pharmacol. 1981 Dec;31(6):875-82. doi: 10.1254/jjp.31.875.
7
Hypotensive effect of SA446, an angiotensin converting enzyme inhibitor, in 2-kidney, 1-clip renal hypertensive and normotensive dogs.
Jpn J Pharmacol. 1987 Apr;43(4):379-87. doi: 10.1254/jjp.43.379.
8
The functional ratio of chymase and angiotensin converting enzyme in angiotensin I-induced vascular contraction in monkeys, dogs and rats.在猴子、狗和大鼠中,血管紧张素I诱导血管收缩过程中糜酶与血管紧张素转换酶的功能比率。
Jpn J Pharmacol. 2000 Dec;84(4):449-54. doi: 10.1254/jjp.84.449.
9
General pharmacological properties of the potent angiotensin converting enzyme inhibitor rentiapril.
Arzneimittelforschung. 1987 Feb;37(2):157-64.
10
Effects of the new angiotensin-I-converting enzyme inhibitor imidapril on the responses of isolated vascular preparations to various agonists.
Arzneimittelforschung. 1992 Apr;42(4):446-51.

引用本文的文献

1
cGAS-STING dependent type I IFN protects against renal colonization in mice.依赖cGAS-STING的I型干扰素可保护小鼠免受肾脏定植。
bioRxiv. 2025 Jun 4:2025.06.02.657349. doi: 10.1101/2025.06.02.657349.
2
Increased Chymase-Positive Mast Cells in High-Grade Mucoepidermoid Carcinoma of the Parotid Gland.腮腺高分化黏液表皮样癌中 Chymase 阳性肥大细胞增多。
Int J Mol Sci. 2023 May 5;24(9):8267. doi: 10.3390/ijms24098267.
3
Chymase as a Possible Therapeutic Target for Amelioration of Non-Alcoholic Steatohepatitis.糜酶作为改善非酒精性脂肪性肝炎的可能治疗靶点。
Int J Mol Sci. 2020 Oct 13;21(20):7543. doi: 10.3390/ijms21207543.
4
Aliskiren: An orally active renin inhibitor.阿利吉仑:一种口服活性肾素抑制剂。
J Pharm Bioallied Sci. 2011 Apr;3(2):189-93. doi: 10.4103/0975-7406.80764.
5
Increased catecholamine secretion contributes to hypertension in TRPM4-deficient mice.TRPM4 缺陷型小鼠中儿茶酚胺分泌增加导致高血压。
J Clin Invest. 2010 Sep;120(9):3267-79. doi: 10.1172/JCI41348. Epub 2010 Aug 2.
6
Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?最佳拮抗肾素-血管紧张素-醛固酮系统:我们需要双重或三重治疗吗?
Drugs. 2010 Jul 9;70(10):1215-30. doi: 10.2165/11537910-000000000-00000.
7
Stimulation of endothelial progenitor cells: a new putative effect of several cardiovascular drugs.刺激内皮祖细胞:几种心血管药物的新潜在作用。
Eur J Clin Pharmacol. 2010 Mar;66(3):219-30. doi: 10.1007/s00228-009-0764-y. Epub 2009 Dec 10.
8
RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.使用血管紧张素受体阻滞剂(ARB)和血管紧张素转换酶抑制剂(ACEI)进行肾素-血管紧张素系统(RAS)阻断:关于理论依据和患者选择的当前观点
Clin Res Cardiol. 2008 Jul;97(7):418-31. doi: 10.1007/s00392-008-0668-3. Epub 2008 May 3.
9
Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? AT1-receptor antagonists?使用血管紧张素转换酶抑制剂和β受体阻滞剂治疗心力衰竭:下一步是什么?血管紧张素Ⅱ1型受体拮抗剂?
Clin Res Cardiol. 2007 Apr;96(4):196-8. doi: 10.1007/s00392-007-0488-x. Epub 2007 Feb 15.
10
Involvement of chymase-mediated angiotensin II generation in blood pressure regulation.糜酶介导的血管紧张素II生成在血压调节中的作用。
J Clin Invest. 2004 Jul;114(1):112-20. doi: 10.1172/JCI20805.